Mylan Gets Tentative OK on Generic Allegra Wednesday April 12, 12:54 pm ET Mylan Laboratories Receives Tentative FDA Approval for Generic Version of Allegra
PITTSBURGH (AP) -- Generic drug manufacturer Mylan Laboratories Inc. said Wednesday it received tentative approval from the Food and Drug Administration for its fexofenadine hydrochloride tablet drug application. The tablets, which are an antihistamine used to treat seasonal allergies, are the generic version of Aventis Pharmaceuticals' Allegra. According to IMS Health, annual domestic sales of Allegra tablets totaled about $1.4 billion last year.
Shares of Mylan Laboratories added 13 cents to $22.30 in afternoon trading on the New York Stock Exchange.